Close

Impax Laboratories Reports First Quarter 2011 Financial Results

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Clinical Trial Supplies Market Worth $8.18 Billion by 2030

The market for clinical trial supplies is about to...

AI in Genomics Market – Setting Pace for Vast Genomic Data

There is no shred of doubt that artificial intelligence...

Recyclable Pharma Packaging: Market To Hit $335B By 2032

There will be a lot more demand for recyclable...

Key Trends Shaping Indian Pharmaceutical Packaging Market

The pharmaceutical business has a major economic influence on...

Impax Laboratories, Inc.reported first quarter ended March 31, 2011 financial results. Larry Hsu, Ph.D., president and CEO, Impax Laboratories, Inc. said, Our revenue related to the sale of our generic and brand products and services other than generic Flomax(R) and Adderall XR(R) increased 11% in the first quarter of 2011. This was primarily due to revenue recognized on milestones achieved during the quarter under development agreements with partners and higher sales of fenofibrate products. “As expected, our first quarter 2011 year over year performance was impacted by the one year anniversary of our exclusive launch of generic Flomax(R), the largest in our history, and to a lesser extent, our continuing inability and frustration in obtaining sufficient generic Adderall XR(R) product. While generic Flomax(R) opportunities don’t occur every quarter, the significant cash generated from this launch will be a large contributor to the external growth initiatives we continue to explore.”

“We believe our pending generic pipeline of 39 products and 77 under development potentially includes other exclusive launch opportunities. We are also enthused about the recent positive phase III results for IPX066, our leading brand product candidate for Parkinson’s disease. All of these pipeline opportunities provide the potential to fuel future growth.”

Latest stories

Related stories

Clinical Trial Supplies Market Worth $8.18 Billion by 2030

The market for clinical trial supplies is about to...

AI in Genomics Market – Setting Pace for Vast Genomic Data

There is no shred of doubt that artificial intelligence...

Recyclable Pharma Packaging: Market To Hit $335B By 2032

There will be a lot more demand for recyclable...

Key Trends Shaping Indian Pharmaceutical Packaging Market

The pharmaceutical business has a major economic influence on...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back